Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE)

Max Kates; Xiangying Chu; Noah Hahn; Eugene Pietzak; Angela Smith; Daniel H Shevrin; Paul Crispen; Stephen B Williams; Siamak Daneshmand; Vignesh T Packiam; Sima Porten; Mary E Westerman; Lynne I Wagner; Michael Carducci

doi:10.1016/j.euf.2023.06.006

Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE)

Eur Urol Focus. 2023 Jul;9(4):561-563. doi: 10.1016/j.euf.2023.06.006. Epub 2023 Jul 6.

Authors

Affiliations

¹ Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA; Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; Department of Oncology, Johns Hopkins University, Baltimore, MD, USA. Electronic address: mkates@jhmi.edu.
² Department of Biostatistics, School of Medicine, Harvard University, Boston, MA, USA.
³ Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA; Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; Department of Oncology, Johns Hopkins University, Baltimore, MD, USA.
⁴ Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁵ Department of Urology, School of Medicine, University of North Carolina, Chapel Hill, NC, USA.
⁶ Northshore Medical Group, Glenview, IL, USA.
⁷ Department of Urology, University of Florida School of Medicine, Gainesville, FL, USA.
⁸ Division of Urology, University of Texas Medical Branch, Galveston, TX, USA.
⁹ Catherine and Joseph Aresty Department of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
¹⁰ Department of Urology, University of Iowa, Iowa City, IA, USA.
¹¹ Department of Urology, UCSF School of Medicine, San Francisco, CA, USA.
¹² Department of Urology, LSU Health Science Center, New Orleans, LA, USA.
¹³ Department of Social Sciences and Health Policy, School of Medicine, Wake Forest University, Winston-Salem, NC, USA.
¹⁴ Department of Oncology, Johns Hopkins University, Baltimore, MD, USA.

PMID: 37422371
PMCID: PMC10515442 (available on 2024-07-06)
DOI: 10.1016/j.euf.2023.06.006

Abstract

EA8212 BRIDGE is a phase 3 randomized trial comparing BCG vs GemDoce for BCG naïve high-risk non-muscle-invasive bladder cancer. This article provides an explanation for the rationale of the clinical trial and details the study design.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Administration, Intravesical
BCG Vaccine / therapeutic use
Clinical Trials, Phase III as Topic
Docetaxel / therapeutic use
Gemcitabine
Humans
Non-Muscle Invasive Bladder Neoplasms*
Randomized Controlled Trials as Topic
Urinary Bladder Neoplasms* / drug therapy

Substances

BCG Vaccine
Docetaxel
Gemcitabine

Abstract

Publication types

MeSH terms

Substances

Grants and funding